A drug for the treatment of cancer
CA 2197139 C · Owner: National Institute Of Immunology · Inventors: Mukherjee, Rama; Jaggi, Manu
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A pharmaceutical composition useful for killing or inhibiting multiplication of cancer cells. It is expected that the pharmaceutical composition will be, useful in preventing inhibiting, or modulating the hypersecretion of VIP somatostatin, bombesin, Substance P, or a combination of VIP somatostatin, bombesin, or , Substance P. The composition may suitably comprise consist of, or consist essentially of a therapeutically effective combination of peptide analogs of somatostatin VIP, bombesin, and Substance P. Also provided is a method of treatment for humans or other animals, suffering from cancer, the method comprising administering a therapeutically effective, dose of the pharmaceutical …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 10, 1997 and granted July 8, 2003. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended February 10, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 10, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.